Want to see RLMD full AI Analyst Report?
RLMD Stock Chart & Stats
$4.59
-$0.02(-0.38%)
At close: 4:00 PM EDT
$4.59
-$0.02(-0.38%)
Day’s Range― - ―
52-Week Range$1.30 - $8.00
Previous CloseN/A
Volume1.65M
Average Volume (3M)1.14M
Market Cap
$466.15M
Enterprise Value$559.91
Total Cash (Recent Filing)$217.73M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.52
Next Earnings
Nov 05, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.92
Shares Outstanding106,669,846
10 Day Avg. Volume862,062
30 Day Avg. Volume1,142,709
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)2.20
Price to Sales (P/S)0.00
P/FCF Ratio-4.16
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$14.33Price Target Upside212.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.62
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Cash RunwayThe substantial cash balance provides funding visibility through planned Phase III development and reduces near-term financing pressure. This gives Relmada time to advance its pipeline and potentially reach important regulatory milestones before requiring additional capital.
Promising NDV-01 EfficacyStrong 12-month Phase II response and durability data support NDV-01’s clinical differentiation and could improve its probability of advancing through registrational development. If replicated, the profile may strengthen future adoption and partnering potential.
Regulatory And Clinical ReadinessFDA alignment and an established site network create a defined route toward registrational testing, reducing development ambiguity. Prepared sites could enable faster trial activation after IND clearance, supporting more efficient execution of the lead program.
Bears Say
Pre-Revenue Operating ModelRelmada has no product revenue to offset its research and corporate costs, leaving results dependent on clinical progress and future financing or partnerships. Continued losses will persist until commercialization, while failed development could limit recovery of invested capital.
Persistent Cash BurnNegative operating and free cash flow shows that the business cannot currently fund itself from operations. Although cash supports the stated runway, sustained development spending may eventually require equity, debt or partnering capital, creating dilution and execution risk.
CMC Delays Threaten Development TimingDependence on manufacturing scale-up, stability work and an external partner creates a material execution bottleneck. Further delays could postpone Phase III initiation, extend the period without revenue and increase development costs before the lead asset reaches regulatory review.
Relmada Therapeutics News
RLMD FAQ
What was Relmada Therapeutics’s price range in the past 12 months?
Relmada Therapeutics lowest stock price was $1.30 and its highest was $8.00 in the past 12 months.
What is Relmada Therapeutics’s market cap?
Relmada Therapeutics’s market cap is $466.15M.
When is Relmada Therapeutics’s upcoming earnings report date?
Relmada Therapeutics’s upcoming earnings report date is Nov 05, 2026 which is in 60 days.
How were Relmada Therapeutics’s earnings last quarter?
Relmada Therapeutics released its earnings results on Aug 06, 2026. The company reported -$0.11 earnings per share for the quarter, beating the consensus estimate of -$0.2 by $0.09.
Is Relmada Therapeutics overvalued?
According to Wall Street analysts Relmada Therapeutics’s price is currently Undervalued.
Does Relmada Therapeutics pay dividends?
Relmada Therapeutics does not currently pay dividends.
What is Relmada Therapeutics’s EPS estimate?
Relmada Therapeutics’s EPS estimate is -0.14.
How many shares outstanding does Relmada Therapeutics have?
Relmada Therapeutics has 106,669,846 shares outstanding.
What happened to Relmada Therapeutics’s price movement after its last earnings report?
Relmada Therapeutics reported an EPS of -$0.11 in its last earnings report, beating expectations of -$0.2. Following the earnings report the stock price went down -8.007%.
Which hedge fund is a major shareholder of Relmada Therapeutics?
Currently, no hedge funds are holding shares in RLMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Relmada Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.33 (212.27% Upside)
$14.33 (212.27% Upside)
Blogger Sentiment
Bullish
RLMD Sentiment 100%
Sector Average 60%
Sector Average 60%
Hedge Fund Trend
Decreased
By 3.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.3%
Last 30 Days ▼ 8.0%
Last 30 Days ▼ 8.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
223.35%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
937.40%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Relmada Therapeutics
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
RLMD Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Overall the call conveyed a constructive and execution-focused tone: Relmada reported a materially strengthened balance sheet (cash +134% YoY) with a cash runway into 2029, compelling 12-month Phase II efficacy and favorable safety for NDV-01, clear FDA-aligned registration pathways, an experienced new CBO, and engaged clinical sites. Key near-term risks center on manufacturing/CMC execution (GMP batch production and stability data), which shifted IND timing toward year-end 2026 and has increased R&D spend and operating cash use. On balance the company appears well-capitalized and positioned to advance registrational programs, but outcomes hinge on resolving manufacturing scale-up and timing.View all RLMD earnings summariesRLMD Stock 12 Month Forecast
Average Price Target
$14.33
▲(212.27% Upside)
Technical Analysis
Ownership Overview
2.82% Insiders
3.68% Mutual Funds
49.86% Other Institutional Investors
32.23% Public Companies and
Individual Investors